This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Anti-Fungal Clinical Strategies: Cased-Based Fungal Management Using a Multidisciplinary Approach

Anti-Fungal Clinical Strategies: Cased-Based Fungal Management Using a Multidisciplinary Approach

Format

Patient Case Simulations

Time to Complete

1 hour

Released

September 26, 2019

Expires

September 26, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Jointly provided by Boston University School of Medicine and Ascendant

Commercial Supporter

This activity was supported by an educational grant from Astellas Pharma.

Program Description

Differential diagnosis of infectious agents and the choice of effective treatment is a true challenge for acquired fungal infections. This interactive CME movie focuses on the multidisciplinary teams used to treat these complicated cases and is designed to take you through two unique fungal management scenarios in which you hold the patient's destiny in your hands. Case 1 follows a patient that acquires a tricky infection after a common routine surgery. Case 2 is an oncology patient with many comorbid conditions that requires a complicated antifungal management strategy.

Intended Audience

This course is designed for patient care teams including infectious disease specialists, hematologists, oncologists, surgical specialists, radiologists, pathologists, medical microbiologists, nurse practitioners, infection control nurses, oncology nurses, physician assistants, and clinical pharmacists that need to treat patients with antifungal agents.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Apply the results of susceptibility testing to identify the most appropriate antifungal agents for patients with invasive fungal infections
  • Utilize knowledge of the pharmacokinetics and pharmacodynamics of antifungal agents to select the most effective treatment regimen including dose, dosing intervals and route of administration to improve clinical outcomes in patients with invasive fungal infections
  • Recognize immunocompromised patients who are at increased risk for invasive mold infections to improve outcomes based on early diagnosis and treatment
  • Apply effective communication and engagement techniques to assess patients for their risk of acquiring an invasive fungal infection, to know when prophylactic antifungal therapy is warranted, and to coordinate care across different specialties and services

Conflict Of Interest Disclosure Policies

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

All planners, speakers, authors, and reviewers involved with content development for continuing education activities provided by Boston University are expected to disclose any real or perceived conflict of interest related to the content of the activity. Detailed disclosures will be included in participant materials or given prior to the start of the activity.

Faculty

Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, CMQ
Professor and Vice Chairman of Medicine for Healthcare Quality
Director, Laboratory of Mycology Research
Division of Infectious Diseases
McGovern Medical School
Medical Director for Epidemiology and Antimicrobial Stewardship
Memorial Hermann Texas Medical Center
Houston, TX

Dr. Ostrosky-Zeichner (Faculty/Reviewer) discloses the following:
Consultant: Astellas, Cidara, Myane, F2G;
Speaker: Merck and Pfizer;
Grants/Clinical Trials with UTHealth: Amplyx, Astellas, Cidara, Scynexis

John Perfect, MD
Professor of Medicine
James B. Duke Professor of Medicine
Chief, Division of Infectious Diseases
Professor in Molecular Genetics and Microbiology
Duke University School of Medicine
Durham, NC

Dr. Perfect (Faculty/Reviewer) discloses the following:
Grants/Research/Consultant: Amplyx, Astellas, F2G, Merck, Pfizer, Scynexis, Viamet

Accredited Provider Disclosures

Elizabeth Drury and Mike Burk, Program Managers, have nothing to disclose.
Stuart Levitz, MD, CME Course Director, has nothing to disclose.

Publishing Staff Disclosures

Maria Class (Planner/Reviewer) – Nothing to disclose.
William Fiedelman (Planner/Reviewer) – Nothing to disclose.
Kelly Kraines (Planner) – Nothing to disclose.
Tracey Roizman (Medical Writer) – Nothing to disclose.
Riccardo Saetti (Planner/Reviewer) – Nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Ascendant Limited. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

Boston University School of Medicine and Ascendant asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all relevant conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue